How to buy Kura Oncology stock | $22.25

Kura Oncology, Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 93 staff and has a market cap (total outstanding shares value) of 0.00.

Kura Oncology stock price (NASDAQ: KURA)

Use our graph to track the performance of KURA stocks over time.

Kura Oncology shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$22.25
52-week range	$16.39 - $43.00
50-day moving average	$20.42
200-day moving average	$26.58
Wall St. target price	$43.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.57

Buy Kura Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Kura Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kura Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kura Oncology price performance over time

Historical closes compared with the close of $22.25 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	5.25%
3 months (2021-05-03)	-16.79%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Kura Oncology financials

Gross profit TTM	$0
Return on assets TTM	-15.15%
Return on equity TTM	-25.62%
Profit margin	0%
Book value	$8.84
Market capitalisation	$1.3 billion

TTM: trailing 12 months

Shorting Kura Oncology shares

There are currently 8.1 million Kura Oncology shares held short by investors – that's known as Kura Oncology's "short interest". This figure is 5.5% down from 8.5 million last month.

There are a few different ways that this level of interest in shorting Kura Oncology shares can be evaluated.

Kura Oncology's "short interest ratio" (SIR)

Kura Oncology's "short interest ratio" (SIR) is the quantity of Kura Oncology shares currently shorted divided by the average quantity of Kura Oncology shares traded daily (recently around 769025.21489971). Kura Oncology's SIR currently stands at 10.47. In other words for every 100,000 Kura Oncology shares traded daily on the market, roughly 10470 shares are currently held short.

However Kura Oncology's short interest can also be evaluated against the total number of Kura Oncology shares, or, against the total number of tradable Kura Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kura Oncology's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Kura Oncology shares in existence, roughly 120 shares are currently held short) or 0.1424% of the tradable shares (for every 100,000 tradable Kura Oncology shares, roughly 142 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kura Oncology.

Find out more about how you can short Kura Oncology stock.

Kura Oncology share dividends

We're not expecting Kura Oncology to pay a dividend over the next 12 months.

Kura Oncology share price volatility

Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $16.39 up to $43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 1.895. This would suggest that Kura Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kura Oncology overview

Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Frequently asked questions

What percentage of Kura Oncology is owned by insiders or institutions?
Currently 2.691% of Kura Oncology shares are held by insiders and 105.513% by institutions. How many people work for Kura Oncology?
Latest data suggests 93 work at Kura Oncology. When does the fiscal year end for Kura Oncology?
Kura Oncology's fiscal year ends in December. Where is Kura Oncology based?
Kura Oncology's address is: 12730 High Bluff Drive, San Diego, CA, United States, 92130 What is Kura Oncology's ISIN number?
Kura Oncology's international securities identification number is: US50127T1097 What is Kura Oncology's CUSIP number?
Kura Oncology's Committee on Uniform Securities Identification Procedures number is: 50127T109